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Objectives: Abdominal aortic aneurysm (AAA) is a
pathologic dilation of the aorta. Inﬂammation of the aortic
wall has been shown to be involved in AAA formation.
Malondialdehyde-acetaldehyde (MAA) adducts are
MAA/protein hybrids with immunogenic, proinﬂamma-
tory, and proﬁbrotic properties. Levels of MAA adducts
are elevated in patients with coronary artery disease; how-
ever, the role of MAA adducts in AAA is unclear. We hy-
pothesize that levels of circulating antibodies against
MAA adducts are increased in patients with AAA.
Methods: Plasma samples were collected from mice
and patients with and without AAA. AAA was induced in
mice by a standard CaCl2 protocol, with matching sham
mice. Plasma levels of anti-MAA antibodies were quantiﬁed
by enzyme-linked immunosorbent assay.
Results: Patients with AAA exhibited higher levels of
immunoglobulin G (IgG) and IgA anti-MAA antibody
subtypes (P ¼ .049 and P ¼ .026, respectively) compared
with control patients. Conversely, IgM anti-MAA anti-
bodies in AAA patients were lower compared with control
patients (P ¼ .018). In CaCl2 treated mice IgG anti-MAA
antibodies were elevated after AAA formation (P ¼ .006).
Conclusions: The pattern of anti-MAA antibodies is
able to distinguish between patients with AAA and patients
with atherosclerosis but no AAA. These results demon-
strate that MAA adducts are associated with AAA and sug-
gest they may play a role in either initiating or propagating
chronic inﬂammation in AAA.
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Objectives: Although medical management of un-
complicated acute type B aortic dissections remains thestandard of care, contemporary data regarding the natural
history of medically treated patients are sparse. The goal
of this study was to evaluate the ability of medical therapy
to prevent long-term complications in patients with acute
type B aortic dissection.
Methods: All patients with acute uncomplicated Type
B aortic dissection that were initially managed medically
between March 1999 and March 2011 were included. Fail-
ure of medical therapy was deﬁned as any death or aortic-
related intervention. Early failure occurred #15 days of
presentation and late failure occurred thereafter. Predictors
of long-term outcomes were determined using Cox pro-
portional hazards models.
Results: A total of 298 patients (61.7%) with medically
managed acute type B dissections were identiﬁed. The
cohort was an average age of 65.9 years at presentation.
There were 37 early failures (12%) including 12 deaths
and 25 interventions (10 thoracic endovascular aortic repair
[TEVAR]/15 open). Aneurysmal degeneration was the
indication for intervention in six (24%). Mean follow-up
was 4.2 years (range, 0.1-14.7 years). There were 174 fail-
ures (58.4%), including 87 deaths and 87 interventions
(24 TEVAR/63 open). Fifty-seven interventions (66%)
were for aneurysmal degeneration. Freedom from interven-
tion was 77.3%6 0.024% at 3 years and 74.2%6 0.025% at
6 years. There were no predictors of freedom from interven-
tion. The intervention-free survival was 55.0% 6 0.030% at
3 years and 41.0% 6 0.032% at 6 years. Age >70 years was
protective against failure (hazard ratio, 0.97; conﬁdence in-
terval, 0.95-0.98, P < .01). Survival was higher in patients
who required intervention at both 3 years (78% vs 73%)
and 6 years (76% vs 58%; P ¼ .018).
Conclusions: Medical therapy of acute uncomplicated
type B dissections is successful in the short-term. However,
theoverall 6-year intervention-free survival is low, and survival
is signiﬁcantly higher in patients who undergo intervention.
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Table.
Ruptured VAA (N ¼ 69) No. (%)
Gender (Male) 43 (62.3)
Age (mean)6SD 5S.8 6 15
Smoking 16 (23.2)
VAA type (pseudoaneurysm) 55 (79.7)
Mean size (mm) (range) 20.5 (3.5-75)
Splenic 19 (27.5)
Celiac 6 (8.7)
SMA 8 (11.6)
Hepatic 16 (23.2)
Renal 1 (1.5)
Pancreaticoduodenal (PDA) 18 (26.1)
Comorbidities
DM 8 (11.6)
CRI 6 (8.7)
ESRD 1 (1.4)
Hypertension 41 (59.4)
Hyperlipidemia 13 (18.8)
CAD 4 (5.9)
COPD 7 (10.1)
CVA 5 (7.2)
Pancreatitis 29 (42)
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Objectives: Most prior single-center series have rec-
ommended repair of asymptomatic renal artery aneurysms
(RAA) >2 cm. This study evaluated the contemporary
management of a large series of RAAs.
Methods: PatientswithRAAswereanalyzedusinga stan-
dardized database by a research consortium of 15 institutions.
Results: A total of 614 RAAs were identiﬁed in 525 pa-
tients at 15 institutions (age, 61; male-to-female ratio ¼
1:2). Seventy-one percent of patients were asymptomatic.
Symptomatic patients had severe hypertension (12%), ﬂank
pain (7%), abdominal pain (6%), and hematuria (4%). Aneu-
rysm location included the main renal artery bifurcation
(40%), main trunk (28%), primary branch (18%), secondary
branch (7%), and pole artery (7%). Most RAAs were saccular
(86%) and calciﬁed (64%). Diameters were 1.86 0.1 cm for
symptomatic RAAs and 1.5 6 0.1 cm for asymptomatic
RAAs (P< .001). Aneurysms were observed (67%; diameter
1.3 6 .1 cm) or surgically treated with open repair (OR;
28%; diameter 2.1 6 .1 cm), or endovascularly (EV; 5%;
diameter 2.36 .2 cm). For OR vs EV, minor complications
were 26% and 10%, respectively (P< .001), and major com-
plications were 1% and 3%, respectively (P ¼ .014). Only
one death occurred, in an EV patient. Conservatively
managed patients were observed for 41 6 4 months with
no ruptures. Fifty-nine RAA >2 cm were treated non-OR
(diameter 2.8 6 .1 cm) with a mean follow-up time of 42
6 10 months. There were no ruptures. The growth rate
for asymptomatic RAA, based on serial imaging, was 0.16
6 0.01 cm/y (calciﬁed ¼ 0.16 6 0.01 cm/y; noncalciﬁed
¼ 0.17 6 0.01 cm/y; P ¼ .913).
Conclusions: This largest study of RAA demonstrates
that (1) asymptomatic RAA rarely rupture, even when >2
cm and not calciﬁed, (2) open repair is associated with signif-
icantminormorbidity but rarely amajormorbidity ormortal-
ity, (3)RAAgrowth rate is 0.1660.01 cm/yandcalciﬁcation
does not protect against growth, (4) the current guideline of
repairing asymptomatic RAA >2 cm is too aggressive.
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Objectives: To review the outcomes of open and
endovascular intervention for intact visceral artery aneu-
rysm (iVAA) and ruptured VAA (rVAA).
Methods: Retrospective review of treated VAA at one
institution from 2003 to 2013.
Results: We identiﬁed 261patients with VAA; of these
155 were repaired (69 ruptured, 86 intact; Table). Pseudo-
aneurysms were more common in rVAA (80%) vs iVAA
(35%; P < .001). rVAA were smaller than iVAA (20.5 vs
27.5mm;P¼ .018) at repair, and theirmost commonpresen-
tation was abdominal pain; 18% were hemodynamically un-
stable. Endovascular intervention was the initial treatment
for 70% (78% for rVAA, 63% for iVAA). Perioperative compli-
cation rate was higher for rVAA (19% vs iVAA 4%; P¼ .003),
as well as 30-day (12% vs 0% iVAA; P¼ .001), 1-year (26% vs
4% iVAA; P< .001), and 3-year (30% vs 7% iVAA; P< .001)
mortality.Lower30-daymortalitywasnotedwith endovascu-
lar repair for rVAA (7% vs 28% open; P ¼ .06). Predictors of
mortality for rVAA included age (HR, 1.098; P ¼ .006)
whereas endovascular repair was protective (HR, 0.231;
P¼ .035).Mean followupwas26months, andKaplan-Meier
estimates of survival were higher for iVAA at 3 years (88% vs
62% iVAA, P ¼ .045). The 30-day reintervention rate was
higher for rVAA (9% vs 1% iVAA; P ¼ .045), but was similar
betweenopenand endovascular repair (8.5%vs15%,P¼NS).
